PLAG1 and posterior cortical atrophy: In the absence of alternative biochemical PCa biomarkers, the majority of PCa screening guidelines still advise the measurement of total serum PSA (tumor (t)PSA>4 ng/mL) as a benchmark marker for the detection of PCa.